

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



November 9, 2023

Company Takara Bio Inc. (Securities code: 4974; Prime Market)  
 Headquarters Nojihigashi 7-4-38, Kusatsu, Shiga, Japan  
 Representative Koichi Nakao, President & CEO  
 Contact Takuya Kakemi, Executive Officer, in charge of PR & IR Department  
 Telephone (+81)77-565-6970  
 Website <https://www.takara-bio.co.jp/>

## Notice Concerning Differences between the Financial Results Forecasts and the Actual Results

Takara Bio Inc. hereby announces that there had been differences between the financial results forecast for the six months ended September 30, 2023 (April 1, 2023 – September 30, 2023), disclosed on August 8, 2023, and the actual results disclosed today, as described below.

### 1. Differences between the financial results forecasts and the actual results

Differences between consolidated financial results forecasts for the six months ended September 30, 2023 (April 1, 2023 – September 30, 2023) and the actual results

	Net sales	Operating profit	Ordinary profit	Net income attributable to owners of the parent	Net income per share
	Million yen	Million yen	Million yen	Million yen	Yen
Previously announced forecasts (A) (Disclosed on August 8, 2023)	19,400	1,100	1,170	650	5.40
Actual results (B)	19,116	1,410	1,598	1,084	9.00
Change (B-A)	(283)	310	428	434	-
Change (%)	(1.5)	28.2	36.7	66.8	-
(Reference) Actual consolidated results for the six months ended September 30, 2022	32,587	10,870	10,955	8,538	70.91

## **(2) Reason for differences**

Net sales fell short of the previous forecast, but operating income exceeded the previous forecast due to efforts to reduce SG&A expenses, including R&D expenses. Furthermore, the depreciation of the yen resulted in foreign exchange gains. As a result, ordinary profit and quarterly net income attributable to owners of the parent also differed from forecasts.

For full-year financial result forecasts for the fiscal year ending March 31, 2024, please refer to the "Notice Concerning Revisions to Financial Results Forecasts" announced today.

---

### Forward-Looking Statements

Statements contained in these materials with respect to the Company's current plans, forecasts, strategies and beliefs that are not historical facts are forward-looking statements about the further performance of the Company and its consolidated subsidiaries. These statements are based on management's assumptions and beliefs in light of information currently available to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.